Cancer vaccine with minimal side effects nearing Phase 3 clinical trials
The vaccine- developed by Dr. Thomas Wagner of U.S.-based Orbis Health Solutions – has already been tested in hundreds of patients with advanced forms of melanoma in Phase 2 clinical trials. The most recent data showed nearly 95% of people given only the vaccine were still alive three years after starting treatment and 64% were still disease-free. Among the most advanced forms of melanoma, disease-free survival after three years for people with stage III disease was 60% in the vaccine-only group, compared to about 39% in the placebo group.